MYBPC3 Antibody (G-1): sc-137182

MYBPC3 Antibody (G-1) is a mouse monoclonal IgG1 antibody that detects MYBPC3 in mouse, rat, and human samples through various applications including western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry, and enzyme-linked immunosorbent assay (ELISA). MYBPC3, or myosin-binding protein C, cardiac, plays a crucial role in regulating cardiac muscle contraction by modulating myosin and actin filament interaction. MYBPC3 is primarily located in the crossbridge-bearing zone of A bands in vertebrate striated muscle, where MYBPC3 contributes to sarcomere structural integrity and function. Precise MYBPC3 localization ensures proper organization of contractile proteins for efficient muscle contraction. Regulatory phosphorylation of MYBPC3 by cAMP-dependent protein kinase upon adrenergic stimulation modulates cardiac contraction, highlighting MYBPC3′s role in responding to physiological demands. Mutations in MYBPC3 can lead to protein truncation, associated with familial hypertrophic cardiomyopathy type 4, characterized by ventricular hypertrophy and potential heart failure. MYBPC3 gene is located on chromosome 11p11.2, making MYBPC3 a significant target for cardiac health and disease research.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

MYBPC3 Antibody (G-1) References:

1. MYBPC3's alternate ending: consequences and therapeutic implications of a highly prevalent 25 bp deletion mutation.  |  Kuster, DW. and Sadayappan, S. 2014. Pflugers Arch. 466: 207-13. PMID: 24327208
2. Mybpc3 gene therapy for neonatal cardiomyopathy enables long-term disease prevention in mice.  |  Mearini, G., et al. 2014. Nat Commun. 5: 5515. PMID: 25463264
3. Reevaluation of the South Asian MYBPC3Δ25bp Intronic Deletion in Hypertrophic Cardiomyopathy.  |  Harper, AR., et al. 2020. Circ Genom Precis Med. 13: e002783. PMID: 32163302
4. Gender- and age-related differences in distinct phenotypes of hypertrophic cardiomyopathy-associated mutation MYBPC3-E334K.  |  Yang, QL., et al. 2021. Heart Vessels. 36: 1525-1535. PMID: 33830315
5. MYBPC3 deficiency in cardiac fibroblasts drives their activation and contributes to fibrosis.  |  Zou, X., et al. 2022. Cell Death Dis. 13: 948. PMID: 36357371
6. Homology-directed repair of an MYBPC3 gene mutation in a rat model of hypertrophic cardiomyopathy.  |  Nie, J., et al. 2023. Gene Ther. 30: 520-527. PMID: 36765144
7. The Relationship between Changes in MYBPC3 Single-Nucleotide Polymorphism-Associated Metabolites and Elite Athletes' Adaptive Cardiac Function.  |  Riguene, E., et al. 2023. J Cardiovasc Dev Dis. 10: PMID: 37754829
8. Base editing effectively prevents early-onset severe cardiomyopathy in Mybpc3 mutant mice.  |  Wu, S., et al. 2024. Cell Res. 34: 327-330. PMID: 38337022
9. MYBPC3-c.772G>A mutation results in haploinsufficiency and altered myosin cycling kinetics in a patient induced stem cell derived cardiomyocyte model of hypertrophic cardiomyopathy.  |  Steczina, S., et al. 2024. J Mol Cell Cardiol. 191: 27-39. PMID: 38648963
10. Atrial Fibrillation Substrate and Catheter Ablation Outcomes in MYBPC3- and MYH7-Mediated Hypertrophic Cardiomyopathy.  |  Haq, IU., et al. 2024. JACC Clin Electrophysiol. 10: 1380-1391. PMID: 38819352

The preferred MYBPC3 antibody is MYBPC3 Antibody (E-7): sc-137180.